Article ; Online: Eculizumab for paroxysmal nocturnal haemoglobinuria
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-
catastrophic health expenditure in Nepalese patients
2023 Volume 4
Abstract: Abstract Paroxysmal nocturnal hemoglobinuria (PNH) results from a mutation in the phosphatidylinositol glycan class-A gene which causes uncontrolled complement activation with resultant intravascular hemolysis and its sequelae. Eculizumab is a terminal ... ...
Abstract | Abstract Paroxysmal nocturnal hemoglobinuria (PNH) results from a mutation in the phosphatidylinositol glycan class-A gene which causes uncontrolled complement activation with resultant intravascular hemolysis and its sequelae. Eculizumab is a terminal complement inhibitor that blocks this complement activation and has revolutionized the treatment of PNH but comes with an enormous price which can have catastrophic health expenditure in low-middle income countries (LMIC) like Nepal. Here, we discuss the potential way forwards in the treatment of PNH in Nepal and other LMICs. |
---|---|
Keywords | Catastrophic health expenditure ; Eculizumab ; Low and middle-income countries ; Orphan drug ; Paroxysmal nocturnal hemoglobinuria ; Nepal ; Medicine ; R |
Language | English |
Publishing date | 2023-06-01T00:00:00Z |
Publisher | BMC |
Document type | Article ; Online |
Database | BASE - Bielefeld Academic Search Engine (life sciences selection) |
Full text online
More links
Kategorien
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.